NCT04360941

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2020-08-11Est. Completion: 2026-07-31

Enrollment target: 45 participants

Locations

The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Hope Clinical Trials Cancer Centre, Leicester, United Kingdom
Barts Cancer Institute, London, United Kingdom
Royal Marsden NHS Foundation Trust, London, United Kingdom
University College London Hospitals NHS Foundation Trust, London, United Kingdom
Nottingham University Hospital, Nottingham, United Kingdom
Weston Park Hospital, Sheffield, United Kingdom

Contact

Orla Batchelorpavement.trial@rmh.nhs.uk 02078082887

Other microbiome trials you might be interested in

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianPhase 1Recruiting

BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial AdenocarcinomaEstrogen Receptor NegativeHER2/Neu NegativeHigh Grade Ovarian Serous AdenocarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Stage IV Uterine Corpus Cancer AJCC v7Triple-Negative Breast Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.